New hope for tick bite survivors: mast cell drugs enter trial
NCT ID NCT07526558
First seen Apr 21, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests whether two drugs that calm mast cells (ketotifen and cromolyn) can safely reduce ongoing symptoms like fatigue, pain, and brain fog in people who had a tick-borne illness. 50 adults aged 21-65 who were treated for Ehrlichiosis or Rocky Mountain Spotted Fever in the last 3 years will receive either the study drugs or standard allergy medicine. The goal is to see if these drugs improve symptom scores and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TICK BITE ILLNESS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.